Skip to content
Life Sciences Series A Founded 2021

VedaBio

VedaBio is a provider of a molecular detection and editing platform using CRISPR Cascade technology. The platform offers near-instant molecular detection of multiplexed analytes without the need for target amplification, and can also be used for diagnostics, research, and therapeutic development. VedaBio leverages CRISPR-based technology to enable rapid, sensitive, and multiplexed molecular detection, transforming…

📍 San Diego, United States · Genomics

Funding snapshot

Last roundSeries A
Amount$40M
Date17 October 2023
Total raised$40M
Team size26

About

VedaBio is a provider of a molecular detection and editing platform using CRISPR Cascade technology. The platform offers near-instant molecular detection of multiplexed analytes without the need for target amplification, and can also be used for diagnostics, research, and therapeutic development. VedaBio leverages CRISPR-based technology to enable rapid, sensitive, and multiplexed molecular detection, transforming how diagnostics and research are conducted in genomics and molecular biology. Founded in 2021 and headquartered in San Diego, United States, VedaBio has raised approximately 40.1 million at the Series A stage with 26 employees and investors including OMX Ventures, Kleinmuntz Associates, Y Combinator, and Tao Capital Partners.

Business model

Genomics > Enabling Technologies > Technology Platforms > Genome Structure and Function

Institutional investors

OMX Ventures Kleinmuntz Associates Y Combinator Tao Capital Partners

Latest coverage

No articles yet.

Raising like VedaBio?

Analyze your pitch deck before your next raise.

Analyze My Deck →